Robert W. Azelby — Chief Commercial Officer and Executive Vice President at Juno Therapeutics

Mr. Robert W. Azelby, also known as Bob, M.B.A. has been Chief Commercial Officer and Executive Vice President of Juno Therapeutics Inc. since November 2, 2015. Mr. Azelby serves as a Vice President of Amgen's North American Commercial Effectiveness Unit and is responsible for sales and marketing functions, including market research, forecasting, sales training and sales operations. Mr. Azelby worked at Amgen, where he served as Vice President and General Manager of Amgen's Oncology Business Unit. At Amgen, he was responsible for the Oncology Business Unit, representing over $6 billion in annual revenue with over 600 sales and marketing personnel. During his 15 year tenure at Amgen, he served as Vice President of Amgen's U.S. Oncology Sales team, which is one of the largest oncology sales teams in the U.S. He garnered international experience as Amgen's General Manager, Netherlands, responsible for all aspects of its commercial operations in that country. He held numerous sales and marketing positions, each with increasing responsibilities. His roles included project management, business development, regional sales management and national marketing director. He has been a Director of Cascadian Therapeutics, Inc. since April 2017. Mr. Azelby is a biotechnology and pharmaceutical industry veteran. Mr. Azelby received his undergraduate degrees in Economics and Religious Studies from the University of Virginia and his Master of Business Administration from Harvard University.